The impact of hepatitis C virus infection on work absence, productivity, and healthcare benefit costs

Hepatology

Volumn 52, Issue 2, 2010, Pages 436-442

  Su, Jun ^a,d   Brook, Richard A ^b   Kleinman, Nathan L ^c   Corey Lisle, Patricia ^a,e  

^a BRISTOL MYERS SQUIBB   (United States)

^b JeSTARx Group   (United States)

^c Human Capital Management Services   (United States)

^d BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^e AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABSENTEEISM; ADULT; ARTICLE; COMORBIDITY; CONTROLLED STUDY; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PRODUCTIVITY; SALARY AND FRINGE BENEFIT;

ABSENTEEISM; AGED; COHORT STUDIES; EFFICIENCY; FEMALE; HEALTH CARE COSTS; HEPATITIS C; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 77955672119     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.23726     Document Type: Article

References (26)

1. Craxi A, Laffi G, Zignego AL. Hepatitis C virus (HCV) infection: a systemic disease. Mol Aspects Med 2008;29:85-95.
2. Centers for Disease Control and Prevention. Hepatitis C Fact Sheet. 2007.
3. Modi A, Liang T. Hepatitis C: a clinical review. Oral Dis 2008;14:10-14.
4. Hoofnagle J. Hepatitis C: the clinical spectrum of disease. HEPATOLOGY 1997;26(Suppl.):15S-20S.
5. Bisceglie D. Natural history of hepatitis C: its impact on clinical management. HEPATOLOGY 2000;31:1014-1018. (Pubitemid 30169951)
6. Chong C, Gulamhussein A, Heathcote E, Lilly L, Sherman M, Naglie G, et al. Health-state utilities and quality of life in hepatitis C patients. Am J Gastroenterol 2003;98:630-638. (Pubitemid 36348537)
7. Davis GL, Balart L, Schiff ER, Lindsay K, Bodenheimer HC Jr, Perrillo RP, et al. Assessing health-related quality of life in chronic hepatitis C using the Sickness Impact Profile. Clin Ther 1994;16:334-343; discussion 271-332.
8. Perrillo R, Rothstein K, Rubin R, Alam I, Imperial J, Harb G, et al. Comparison of quality of life, work productivity and medical resource utilization of peginterferon alpha 2a vs the combination of interferon alpha 2b plus ribavirin as initial treatment in patients with chronic hepatitis C. J Viral Hepat 2004;11:157-165. (Pubitemid 38365767)
9. McHutchison JG, Ware JE Jr, Bayliss MS, Pianko S, Albrecht JK, Cort S, et al. The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity. J Hepatol 2001;34:140-147. (Pubitemid 32102564)
10. Charlson M, Pompei P, Ales K, MacKenzie C. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 1987;40:373-383. (Pubitemid 17055592)
11. Kleinman NL, Brook RA, Patel PA, Melkonian AK, Brizee TJ, Smeeding JE, et al. The impact of gout on work absence and productivity. Value Health 2007;10:231-237.
12. Kleinman NL, Brook RA, Rajagopalan K, Gardner HH, Brizee TA, Smeeding JE. Lost time, absence costs, and reduced productivity output for employees with bipolar disorder. J Occup Environ Med 2005;47:1117-1124.
13. Brook RA, Kleinman NL, Choung RS, Melkonian AK, Smeeding JE, Talley NJ. Functional Dyspepsia Impacts Absenteeism and Direct and Indirect Costs. Clin Gastroenterol Hepatol 2010 Mar 19. [Epub ahead of print].
14. Wahlqvist P, Brook RA, Campbell SM, Wallander MA, Alexander AM, Smeeding JE, et al. Objective measurement of work absence and on-the-job productivity: a case-control study of US employees with and without gastroesophageal reflux disease. J Occup Environ Med 2008;50:25-31.
15. Ai C, Norton EC. Standard errors for the retransformation problem with heteroscedasticity. J Health Econ 2000;19:697-718.
16. Blough DK, Madden C, Hornbrook MC. Modeling risk using generalized linear models. J Health Econ 1999;18:153-171.
17. Manning WG, Mullahy J. Estimating log models: to transform or not to transform? J Health Econ 2001;20:461-494.
18. Jewell NP. Statistics for Epidemiology. Boca Raton, FL: Chapman & Hall/CRC; 2004.
19. Zeuzem S, Yoshida EM, Benhamou Y, Pianko S, Bain VG, Shouval D, et al. Albinterferon alfa-2b dosed every two or four weeks in interferon- naive patients with genotype 1 chronic hepatitis C. HEPATOLOGY 2008;48:407-417.
20. Joish VN, Donaldson G, Stockdale W, Oderda GM, Crawley J, Sasane R, et al. The economic impact of GERD and PUD: examination of direct and indirect costs using a large integrated employer claims database. Curr Med Res Opin 2005;21:535-544.
21. Poelmans J, Tack J. Extraoesophageal manifestations of gastro-esophageal reflux. Gut 2005:1492-1499
22. Liker H, Jones R, Ducrotte P. The effect of sleep disturbance due to gastroesophageal reflux disease on work and leisure productivity: results from a multinational survey [Abstract]. Gastroenterology 2005;128:A386.
23. Johnson D, Orr WC, Crawley JA, Traxler B, McCullough J, Brown KA, et al. Effect of esomeprazole on nighttime heartburn and sleep quality in patients with GERD: a randomized, placebo-controlled trial. Am J Gastroenterol 2005;100:1914-1922.
24. Garson G. Statnotes: An Online Textbook. North Carolina State University. http://faculty.chass.ncsu.edu/garson/PA765/statnote.htm. Accessed April 2010.
25. Lerner D, Amick BC, Lee JC, Rooney T, Rogers WH, Chang H, et al. Relationship of employee-reported work limitations to work productivity. Med Care 2003;41:649-659.
26. Su J, Kleinman NL, Brook RA, Melkonian AK, Smeeding JE, Corey- Lisle P. The impact of hepatitis-C viral (HCV) treatment on work absence and productivity. Gastroenterology 2009;16(Suppl.):M1810.